semaglutide on shortage list Federal judge upholds FDA's removal of Ozempic, Wegovy from drug Ozempic and Wegovy officially moved

Studies in rodents have shown that GLP-1 receptor agonists, including semaglutide, cause dose-dependent and treatment-duration-dependent thyroid C-cell tumors

The evaluation process also identifies potential contraindications such as certain medical conditions, medication interactions, or pregnancy status that would make treatment inadvisable

Research shows that patients on GLP-1 therapy experience metabolic adaptation within weeks of starting treatment, shifting their set point for temperature regulation downward

Wegovy (Semaglutide) is a weekly injection clinically proven for significant weight loss

It works in the brain to control hunger and food intake.